Recon: Perrigo launches over-the-counter birth control pill in the US; Drugmakers make counteroffers in first round of Medicare price negotiations

• Massachusetts lawmakers consider $1 billion proposal to bolster region’s life science leadership (STAT)
• Perrigo's over-the-counter birth control launch takes flight in the US (Fierce Pharma)
• US court to weigh Obamacare mandate to cover HIV drug, cancer screenings (Reuters)
• Drugmakers submit counteroffers as part of first round of drug price negotiations (Endpoints) (Reuters)
• Federal regulators, scrambling to keep up with AI in health care, team up with industry to set standards (STAT)
• Pfizer to 'wind down construction' of Seagen's $350M manufacturing site (Endpoints)
• Pfizer stops buildout of $350M Seagen plant, leaving 120 workers' roles in question (Fierce Pharma)
• FDA pushes back decision on Zevra’s drug; Revance to raise $100M (Endpoints)
• RSV vaccines may raise risk of Guillain-Barré syndrome, FDA preliminary analysis finds (Fierce Pharma)

• India's Serum boosts supply of cervical cancer shots ahead of government's mass drive (Reuters)
• Spain's Catalonia hands out free reusable menstruation products (Reuters)
• Three Major Regulators Launch Pilot To Reduce Duplication Of GMP Inspections (Pink Sheet)
• Teva slammed for breaching drug promotion code in earned media article (Fierce Pharma)
• GSK's new HIV drug formula could support longer dosing intervals (Reuters)

• He’s 19 months old and has one of the world’s rarest diseases. His parents are determined to find a cure (STAT)
• Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows (STAT)
• Q&A: Stem cell biologist predicts human embryo models could pave the way to organ transplants (STAT)
• In a first, fetal cell organoids generated from amniotic fluid, new study reports (STAT)
• Sanofi’s CEO on the consumer divestiture, a future in weight loss, antitrust and AI’s secrecy wave: Q&A (Endpoints)
• Merck KGaA bags another molecular glue deal for $16M upfront, this time with C4 (Endpoints)
• Exclusive: Nocion raises $62M for different approach to chronic cough than Merck, GSK (Endpoints)
• Ally Bridge beefs up 'new generation' as investment firm passes 10-year mark (Endpoints)
• Cormorant nears the close of fifth private healthcare fund as biotech industry sees greener pastures (Endpoints)
• Akero's fatty liver disease drug lessens scarring in mid-stage trial (Reuters)
• Lilly CEO: Affordable Generics And IP Support 'Not Incompatible Ideas' (Pink Sheet)
• With Takeda out of the picture, J&J’s Rybrevant moves into first line in lung cancer subtype (Fierce Pharma)

• Medicare is a tricky market for telehealth companies. Why is Talkspace betting on it? (STAT)
• One Step Closer to Final: The LDT Rule Arrives at OMB, Making A Lawsuit More Likely (FDA Law Blog)
• Baxter considers selling kidney care unit to private equity (MedTech Dive)
• Dexcom, Novo Nordisk call for FDA input on digital diabetes detection devices (MedTech Dive)
• GE Healthcare recalls incubators due to risk of newborns falling (MedTech Dive)

• Explaining Change Healthcare and the gravity of its cyberattack (STAT)
• Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people (STAT)
• Too many donor organs go to waste. Here’s how to get them into the patients who need them (STAT)
• Walgreens CEO says no plans to sell specialty pharmacy unit (Reuters)